Recombinant Human CCL16/HCC-4, N-GST

Description of Recombinant Human CCL16/HCC-4, N-GST

Introduction to Recombinant Human CCL16/HCC-4, N-GST

Recombinant Human CCL16/HCC-4, N-GST is a genetically engineered protein that has been produced in the laboratory using recombinant DNA technology. This protein is a member of the chemokine family, which are small signaling proteins involved in immune responses and inflammation. CCL16/HCC-4, also known as liver-expressed chemokine (LEC), is a chemokine that is primarily expressed in the liver and has been shown to play a role in various diseases, making it a potential drug target for therapeutic intervention.

Structure of this protein

Recombinant Human CCL16/HCC-4, N-GST is a fusion protein consisting of three components: the amino-terminal region of human CCL16/HCC-4, a glutathione S-transferase (GST) tag, and a linker sequence. The amino-terminal region of CCL16/HCC-4 is responsible for its biological activity, while the GST tag allows for easy purification of the protein. The linker sequence connects the two components and ensures proper folding of the protein.

Activity of Recombinant Human CCL16/HCC-4, N-GST

Recombinant Human CCL16/HCC-4, N-GST has been shown to have chemotactic activity, meaning it can attract specific types of immune cells to a particular location. This activity is mediated by binding to its receptor, CCR1, which is expressed on the surface of immune cells. The chemotactic activity of CCL16/HCC-4 is important in immune responses, as it helps to recruit immune cells to sites of infection or inflammation.

In addition to its chemotactic activity, CCL16/HCC-4 has also been shown to have angiogenic properties. It can promote the growth of new blood vessels, which is important for wound healing and tissue repair. This activity is mediated by binding to a different receptor, CCR2, which is expressed on the surface of endothelial cells, the cells that line blood vessels.

Application of Recombinant Human CCL16/HCC-4, N-GST

Due to its chemotactic and angiogenic activities, Recombinant Human CCL16/HCC-4, N-GST has potential applications in various diseases. One of the most promising areas of research is in the treatment of liver diseases. CCL16/HCC-4 is highly expressed in the liver and has been shown to play a role in liver fibrosis, a condition characterized by excessive scarring of the liver. By targeting CCL16/HCC-4, it may be possible to reduce the progression of liver fibrosis and improve liver function.

In addition, CCL16/HCC-4 has been implicated in other diseases such as cancer, cardiovascular disease, and autoimmune diseases. By targeting CCL16/HCC-4, it may be possible to modulate immune responses and reduce inflammation, which could have therapeutic benefits in these diseases.

Conclusion

Recombinant Human CCL16/HCC-4, N-GST is a genetically engineered protein with chemotactic and angiogenic activities. Its structure consists of the amino-terminal region of CCL16/HCC-4, a GST tag, and a linker sequence. This protein has potential applications in various diseases, particularly in the treatment of liver diseases. Further research and development of Recombinant Human CCL16/HCC-4, N-GST may lead to new therapeutic options for these diseases, making it an important drug target in the field of medicine.